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Background: Single-nucleotide polymorphisms (SNPs) in tumor necrosis factor alpha-inducible protein 3 (TNFAIP3)
gene have been linked to inflammatory, immunological and malignant diseases. Hepatitis B virus (HBV) infection is
characterized by immunopathogenesis. This study investigated the association of rs2230926, a nonsynonymous SNP
in TNFAIP3 gene, with chronic HBV infection.
Methods: Four hundred and fifty-five patients with chronic HBV infection with clinical diseases of chronic hepatitis
(n = 183), liver cirrhosis (n = 167) and hepatocellular carcinoma (n = 105), 92 HBV infection resolvers and 171 healthy
controls were included. All subjects were of Chinese Han ethnicity. Genotyping of rs2230926 was carried out by
polymerase chain reaction-restriction fragment length polymorphism method.
Results: The gender and age between HBV patients, HBV infection resolvers and healthy controls had no statistical
difference. The genotypes of rs2230926 in HBV patients, HBV infection resolvers and healthy controls are in
Hardy-Weinberg equilibrium. The genotype and allele frequencies of TNFAIP3 rs2230926 polymorphism between
HBV patients, HBV infection resolvers and healthy controls had no significant difference. The genotype and allele
frequencies of TNFAIP3 rs2230926 polymorphism between HBV patients with chronic hepatitis, liver cirrhosis and
hepatocellular carcinoma also showed no significant difference.
Conclusions: The TNFAIP3 rs2230926 polymorphism is not suggested to be associated with the susceptibility of
chronic HBV infection or the progression of HBV-related diseases in this study. Replicative studies and studies in
large control and HBV patient populations of different ethnicity by genotyping more polymorphisms in TNFAIP3
gene are needed.
Keywords: Hepatitis B virus, TNFAIP3, Polymorphism, Susceptibility, Clinical diseaseBackground
Hepatitis B virus (HBV) infection is a major cause of
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unless otherwise stated.(HCC) [1]. The development and progress of HBV-
associated liver disease is regarded as a result of the
interplay between the virus and the host’s immune
response [2,3]. The intensity of immuno-inflammatory
responses of the hosts to various levels of the HBV
viral replication characterizes the natural course of
chronic HBV infection and has been extensively studied,
showing that immunoinflammatory responses associated
with various types of cells are involved in the course [4-9].
In particular, T cell exhaustion, which is characterized
by a hierarchical and progressive loss of T-cell functionsThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Up-regulation of inhibitory molecules and down-regulation
of effector function are characteristics of the exhaustion
of HBV-specific T cells [11,12]. Because the excess of
inhibitory molecules is among the critical factors driving
T cell exhaustion in chronic HBV infection, blockade of
these inhibitory molecules including programmed death-1
(PD-1), cytotoxic T-lymphocyte-associated antigen 4
(CTLA-4) and T-cell immunoglobulin domain and mucin
domain-containing molecule-3 (Tim-3) has been dem-
onstrated to reconstitute the potential of functional
HBV-specific T cells [11,12]. Genetically, single-nucleotide
polymorphisms (SNPs) in PD1 [13], CTLA4 [14] and
TIM3 [15] have also been demonstrated to be associated
with the disease progression of chronic HBV infection.
However, the role of these molecules in chronic HBV
infection appeared to be non-redundant and the rescue of
HBV T cell specificities by their blockade was incomplete
and not all patients responded to these strategies, suggesting
the possible role of other inhibitory molecules.
Tumor necrosis factor alpha-inducible protein 3
(TNFAIP3, also known as A20), a cytoplasmic zinc finger
protein with ubiquitin-modifying activity, has been identi-
fied as a negatively regulating molecule that inhibits nuclear
factor kappa-B (NF-κB) activity and tumor necrosis factor
(TNF)-mediated programmed cell death [16-19]. Human
genetic studies have linked polymorphisms in the TNFAIP3
gene to inflammatory, autoimmune and malignant diseases
[20]. Among the SNPs in TNFAIP3 gene, rs2230926, a non-
synonymous common coding SNP in exon 3 of TNFAIP3
which introduces the amino acid substitution of phenyl-
alanine to cysteine at amino acid position 127 of the
protein, has been functionally shown to possibly influ-
ence the mRNA expression of TNFAIP3 and the
inhibitory activity of TNFAIP3 [21-23]. Furthermore,
TNFAIP3 rs2230926 polymorphism has been demon-
strated to be significantly associated with systemic
lupus erythematosus (SLE) among multiple ethnic
populations [21,24-29] and other autoimmune diseases
such as Sjögren’s syndrome, Crohn’s disease, psoriasis
and rheumatoid arthritis [30,31].Table 1 Demographics and Hardy-Weinberg equilibrium of th
patients, HBV infection resolvers and healthy controls and th
Patients (n = 455)
Sex (male/female) 347/108
Age [year, mean ± SD (range)] 41.8 ± 13.2 (18–77)





HBV, hepatitis B virus; HWE, Hardy-Weinberg equilibrium; HCC, hepatocellular carcinThe possible role of TNFAIP3 in chronic HBV infection
remains largely unknown. Given the functional relevance,
the common frequency and the strong association with
immune-associated diseases of rs2230926 polymorph-
ism in the TNFAIP3 gene as well as the involvement
of immunoregulatory and inflammatory responses in
chronic HBV infection, the aim of this study was to
examine the possible association between TNFAIP3
rs2230926 polymorphism and chronic HBV infection
in a Chinese Han population.
Methods
Patients and controls
Patients with chronic HBV infection were recruited from
the First Affiliated Hospital, School of Medicine, Xi’an
Jiaotong University, a tertiary hospital in the northwest
China. All patients were tested to be negative for markers
of hepatitis C virus (HCV) and human immunodeficiency
virus (HIV). Coexistence of autoimmune, alcoholic or
metabolic liver disease was also excluded. Patients who
had never been treated with nucleos(t)ide analogues or
interferon (IFN)-α were eligible for inclusion. Patients
were diagnosed as a clinical disease of chronic hepatitis
(CH), liver cirrhosis (LC) or HCC based on history of
HBV infection, HBsAg/anti-HBs, HBeAg/anti-HBe and
anti-HBc serostatus, HBV DNA level, biochemical liver
function, α-fetoprotein (AFP) level, and ultrasonography
and/or computerized tomography (CT)/ magnetic reson-
ance imaging (MRI) as described previously [14]. Moreover,
HBV infection resolvers and healthy individuals were
recruited as controls. The resolution of HBV infection was
based on normal liver biochemistries and seropositivity for
anti-HBs and anti-HBc. Healthy controls were those who
had normal liver biochemistries, no history of hepatitis B,
and seropositivity for anti-HBs only or seronegativity for
HBV markers. In total, 455 patients with chronic HBV
infection [age, 41.8 ± 13.2 (18–77) years; male/female,
347/108] were enrolled. The clinical diagnoses of the
patients were 183 chronic hepatitis, 167 liver cirrhosis and
105 HCC (Table 1). For comparison, 92 HBV infection re-
solvers [age, 44.3 ± 15.1 (18–78) years; male/female, 63/29]e genotypes of rs2230926 G/T polymorphism in HBV
e clinical diagnosis of HBV patients
Resolvers (n = 92) Controls (n = 171) P
63/29 116/55 0.06
44.3 ± 15.1 (18–78) 42.7 ± 15.8 (19–76) 0.45
0.19 0.08
oma.
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male/female, 116/55] were also recruited (Table 1).
Determination of serum HBV markers and liver
biochemistry
Serum HBV markers including HBsAg, anti-HBs,
HBeAg, anti-HBe and anti-HBc were detected using
ELISA from Beijing Wantai Biological Pharmacy (Beijing,
China). Biochemical liver function including alanine
aminotransferase (ALT) and aspartate aminotransferase
(AST) levels (IU/L) was assayed on the Olympus AU5400
automatic biochemical analyzer (Olympus Corporation,
Mishama, Japan). Serum HBV DNA levels (IU/ml) were
quantitatively determined using hepatitis B virus fluores-
cence polymerase chain reaction diagnostic kit manufac-
tured by Da An Gene Co., Ltd. of Sun Yat-Sen University
(Guangzhou, China) according to the instruction. Serum
AFP levels (ng/ml) were measured using automated
Eleceyes (Roche Diagnostics, Mannheim, Germany).
Genotyping of TNFAIP3 rs2230926 polymorphism
Genomic DNA was extracted from EDTA-treated
peripheral blood using TIANamp Genomic DNA Kit
[Tiangen Biotech (Beijing) Co., Ltd., Beijing, China]
according to manufacturer’s instruction. Genotyping
of TNFAIP3 rs2230926 G/T polymorphism was carried out
by DNA amplifications with polymerase chain reaction
(PCR) and specific primer sets, followed by the re-
striction fragment length polymorphism (RFLP) method.
The primers used for amplification are: Forward:
(12169–12188) 5′-CTCCTTTGCAGTTGGTGTCA-3′
and Reverse: (12698–12717) 5′-GCTTCGCTTAGC
CAAATTCA-3′ [32], according to TNFAIP3 sequence
(NG_032761). The PCR was carried out in a volume
of 25 μl reaction, containing 12.5 μl 2 × Taq plus PCR
Mix (Xi’an Runde Biotechnology, Xi’an, China),1.0 μl
(10 μM) forward primer, 1.0 μl (10 μM) reverse primer, 6
μl genomic DNA and 4.5 μl sterile double distilled water.
The reaction mixture was pre-heated at 94°C for 5 min,
then amplified 30 cycles using the following program:
heated at 94°C for 30 s, annealing at 60°C for 30 s and
extension at 72°C for 1 min, and lastly extended at 72°C
for 10 min. The undigested PCR product has a length of
549 bp. The restriction fragments of the polymorphism
were obtained using restriction endonuclease Fnu4HI
[New England Biolabs (Beijing) Ltd., Beijing, China]
according to the instruction of the manufacturer. The
Fnu4HI has a restriction site on the PCR products with G
allele (12486–12490, TCAGC > GCAGC). Digested
fragments were analyzed by electrophoresis on 2% agarose
gels stained with ethidium bromide. The genotypes of
the polymorphism were determined according to the
digestion patterns: genotype TT: a fragment of 549
bp, genotype GT: 3 fragments of 549 bp, 319 bp and230 bp, respectively, and genotype GG: 2 fragments
of 319 bp and 230 bp, respectively.
Statistical analysis
Statistical analysis was performed by SPSS software
version 16.0 (SPSS, Inc., Chicago, IL). The frequency
of genotypes and alleles was determined by direct
gene counting method. Hardy-Weinberg equilibrium of
the polymorphism was tested with χ2 test. The association
between polymorphism and disease status was tested
using χ2 test for contingency tables or Fisher’s exact
test where applicable [33]. Odds ratios (OR) and its
95% confidence interval (CI) were calculated to estimate
the risk conferred by a particular genotype and allele. A
P value < 0.05 was considered statistically significant.
Ethical approval and consent
This study was approved by the Review Board of the
First Affiliated Hospital, School of Medicine, Xi’an
Jiaotong University and conducted in accordance with
the Declaration of Helsinki. Written informed consent
was obtained from all the participants for the publication
of this report.
Results
Demographics and Hardy-Weinberg equilibrium of the
genotypes of rs2230926 in the study subjects
The demographics of the study subjects and the clinical
diagnosis of the HBV patients are presented in Table 1.
All subjects were of Chinese Han ethnicity. The gender
and age between HBV patients, HBV infection resolvers
and healthy controls had no statistical difference (Table 1).
The genotypes of rs2230926 in HBV patients, HBV infec-
tion resolvers and healthy controls are in Hardy-Weinberg
equilibrium (P > 0. 05, Table 1).
Genotype and allele frequencies of rs2230926
polymorphism in hepatitis B virus (HBV) patients, HBV
infection resolvers and healthy controls
The genotype and allele frequencies of rs2230926
polymorphism in HBV patients, HBV infection resolvers
and healthy controls are shown in Table 2. There were
no significant differences in the genotype and allele
frequencies of rs2230926 polymorphism between HBV
patients, HBV infection resolvers and healthy controls
(Table 2).
Genotype and allele frequencies of rs2230926
polymorphism in hepatitis B virus (HBV) patients with
different clinical diagnosis
The genotype and allele frequencies of rs2230926
polymorphism in HBV patients with different clinical
diagnosis are shown in Table 3. There were no significant
differences in the genotype and allele frequencies of
Table 2 Genotype and allele frequencies of the rs2230926 G/T polymorphism in hepatitis B virus (HBV) patients, HBV
infection resolvers and healthy controls
Patients Resolvers Controls P Patients vs. resolvers Patients vs. controls Resolvers vs. controls
(n = 455) (n = 92) (n =171) P OR (95% CI) P OR (95% CI) P OR (95% CI)
Genotype
TT 429 (94.3) 84 (91.3) 164 (95.9) 0.31 0.28 0.64 (0.28-1.45) 0.42 1.42 (0.61-3.34) 0.13 2.23 (0.78-6.36)
GT 26 (5.7) 8 (8.7) 7 (4.1)
Allele
T 884 (97.1) 176 (95.7) 335 (98.0) 0.32 0.29 1.55 (0.69- 3.47) 0.43 0.71 (0.31-1.65) 0.13 0.46 (0.16-1.29)
G 26 (2.9) 8 (4.4) 7 (2.1)
Data are presented as n (%).
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different clinical diagnosis (Table 3).
Discussion
This study investigated the possible association of
TNFAIP3 nonsynonymous SNP rs2230926 with chronic
HBV infection in Chinese Han population. The genotype
and allele frequencies of rs2230926 polymorphism in the
healthy control population of this study were: genotype
TT, 95.91%; genotype GT, 4.09%; allele T, 97.95%; and
allele G, 2.05%. Considering the minor allele, the allele
G in this study was lower than other studies in Chinese
Han populations (4.5%-5.9%) [27,34] and Korean population
(5.3%) [35]. Although studies in Chinese Han population
revealed very low frequency of genotype GG (0.091%-0.3%)
[27,34], we did not detect genotype GG in both the control
and patient populations and this is consistent with
the findings in Korean population [35]. These results
indicate that the rs2230926 polymorphism may vary
greatly even in populations with genetic vicinity.
This study showed that the genotype and allele frequen-
cies of TNFAIP3 rs2230926 polymorphism between HBV
patients, HBV infection resolvers and healthy controls and
among HBV patients with different clinical diagnosis had
no significant differences, suggesting that this polymorph-
ism might not contribute to the susceptibility of chronic
HBV infection or the progression of HBV-related diseases.
Previous studies showed that this polymorphism isTable 3 Genotype and allele frequencies of rs2230926 G/T po
different clinical diagnosis
Chronic hepatitis Cirrhosis HCC P Chronic hepa
(n = 183) (n = 167) (n = 105) P O
Genotype
TT 175 (95.6) 158 (94.6) 96 (91.4) 0.33 0.66 1
GT 8 (4.4) 9 (5.4) 9 (8.6)
Allele
T 358 (97. 8) 325 (97.3) 201 (95.7) 0.34 0.66 1
G 8 (2. 2) 9 (2.7) 9 (4.3)
Data are presented as n (%). HCC, hepatocellular carcinoma.associated with other diseases especially autoimmune
disorders [21,24-31]. It is therefore suggested that the
significance of this genetic polymorphism might be
restricted to specific diseases.
It is noteworthy that recent studies proposed that a
pair of tandem polymorphic dinucleotides (rs148314165,
rs200820567, referred to as TT > A) located in the
genomic DNA 30 kb telomeric of TNFAIP3 may be the
most likely candidate variants responsible for association
with SLE and the TT > A risk alleles are carried on a risk
haplotype that is associated with hypomorphic expression
of TNFAIP3 transcripts and protein and the TT > A risk
variants attenuate TNFAIP3 expression through inefficient
delivery of NF-kB to the TNFAIP3 promoter [36,37],
evidencing the critical functional role of TT > A in the
genetic predisposition to autoimmune diseases. Therefore,
considering the relevance of TNFAIP3 molecule to
the regulation of NF-κB activity and TNF-mediated
programmed cell death [16-19] and the involvement
of NF-κB activity and programmed cell death in HBV
infection [38-40], the possible predisposition effect of
this TT > A polymorphism in chronic HBV infection
deserves investigation in future studies.
It should be noted that this study has limitations. The
findings were preliminary results from a limited number of
HBV patients and controls of Chinese Han population. The
study only analyzed the association of one polymorphism
with cross-sectional diseases in chronic HBV infection. Thelymorphism in hepatitis B virus (HBV) patients with
titis vs. Cirrhosis Chronic hepatitis vs. HCC Cirrhosis vs. HCC
R (95% CI) P OR (95% CI) P OR (95% CI)
.25 (0.47-3.31) 0.15 2.05 (0.77-5.49) 0.30 1.65 (0.63-4.29)
.24 (0.47-3.25) 0.15 2.00 (0.76-5.28) 0.31 1.62 (0.63- 4.14)
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compromised the probative value of the findings.
Therefore, further studies in large patient and control
populations of different ethnicity with longitudinal
follow-up of the patients by genotyping more poly-
morphisms in TNFAIP3 gene are needed to clarify the
possible effect of TNFAIP3 polymorphisms on chronic
HBV infection and HBV-related diseases.
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